Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Yes-associated protein 1 (YAP1) is a key transcriptional coactivator and the primary downstream effector of the evolutionary conserved Hippo signaling pathway. When the Hippo pathway is active, upstream kinases (such as MST1/2 and LATS1/2) phosphorylate YAP1, leading to its cytoplasmic sequestration and proteasomal degradation. Conversely, when the Hippo pathway is inactivated or dysregulated (often due to mutations in tumor suppressors like NF2 or FAT1), unphosphorylated YAP1 translocates to the nucleus. Because YAP1 lacks a DNA-binding domain, it binds to TEA domain (TEAD) family transcription factors to drive the expression of genes involved in cell proliferation, survival, and migration, such as CTGF and CYR61.
Aberrant activation of YAP1 signaling is a major driver of tumorigenesis, metastasis, and drug resistance in various malignancies, including malignant pleural mesothelioma, colorectal cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. Consequently, the YAP1-TEAD transcriptional complex has emerged as a highly attractive therapeutic target. Drug development strategies include TEAD palmitoylation inhibitors (such as VT3989 and ODM-212) that destabilize the TEAD-YAP1 interaction, direct protein-protein interaction disruptors (such as IAG933), and antisense oligonucleotides (such as ION537) that target YAP1 mRNA for degradation. Notable clinical safety concerns associated with targeting this pathway include reversible albuminuria/proteinuria, QTc prolongation, and potential impairment of normal tissue regeneration and wound healing.
TEAD palmitoylation inhibition, YAP/TAZ-TEAD protein-protein interaction disruption, antisense oligonucleotide-mediated mRNA degradation
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Yes-associated protein 1 (YAP1) (YAP1).